cm338

mAbexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 11, 2021 (NCT05186285)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05775042Phase 2May 8, 2023Keymed Biosciences Co.Ltd, Peking University
NCT05371379Phase 1Jun 1, 2022Keymed Biosciences Co.Ltd
NCT05186285Phase 1Dec 11, 2021Keymed Biosciences Co.Ltd
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Keymed Biosciences Co.LtdFor profit3322021
Peking UniversityAcademic/Hospital1012023
2 organizations
Page 1 / 1